Product
BG-68501
1 clinical trial
9 indications
Indication
Breast CancerIndication
Small Cell Lung CancerIndication
Ovarian CancerIndication
Stomach CancerIndication
Hormone-receptor-positive Breast CancerIndication
Advanced Solid TumorIndication
Endometrial CancerIndication
Prostate CancerClinical trial
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-31